For example, the small molecule tyrosine kinase inhibitors (TKIs) were effective for patients with advanced lung adenocarcinoma with the somatic mutation of epidermal growth factor receptor (EGFR) and the rearrangement of echinoderm microtubule-associated protein-like 4 (EML4) with anaplastic lymphoma kinase (ALK) (Paez et al., 2004; Soda et al., 2007; Robichaux et al., 2018; Ramalingam et al., 2020). The gene discussed is EGFR; the disease is lung adenocarcinoma.